论文部分内容阅读
乙酸氟卡胺(Flecainide,2,5-22(2,2,2-三氟乙氧基)-N-(2-哌啶甲基)乙酸苯甲酰胺)可有效抑制狗及小鼠的实验性室性心律失常.初步研究提示氟卡胺具有第Ⅰ类抗心律失常药物的特性,即减慢心房、连接处与心室的传导,并延长其不应期.氟卡胺口服后基本完全吸收.为估价口服氟卡胺对患频繁室性异位除极患者的疗效及安全性,作者对11例频繁发作室性异位除极的患者进行了研究.方法:11例患者中7例曾用奎尼丁、丙吡胺、心得安与普鲁卡因酰胺无效.入院前停用抗心律失常药物.入院头2日给予安慰剂胶囊每日2次,记
Flecainide (2,5-22 (2,2,2-trifluoroethoxy) -N- (2-piperidinylmethyl) benzamide) can effectively inhibit the experiment of dogs and mice Ventricular arrhythmia. Preliminary studies suggest that flecainide with class Ⅰ antiarrhythmic drugs that slow down the atria, junction and ventricular conduction, and prolong its refractory period. Flecarbamide after oral administration of almost completely absorbed To evaluate the efficacy and safety of oral flecainide in patients with frequent ventricular ectopic depolarizations, we conducted a study of 11 patients with frequent ectopic ectopic depolarization.Methods: Of the 11 patients, 7 Pethidine, propranolol, propranolol, and procaineamide. Antiarrhythmic drugs were discontinued before admission. Placebo capsules were administered twice daily on the first 2 days of admission